Arianna Warfel
Gerontology · Cincinnati, OHNPI 1922449859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,341 and has fallen 93.7% since, to $148 in 2025. Among gerontology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$775
- Abbott$654
- Lilly USA, LLC$415
- Pfizer$309
- plus $3K from 24 others
What the payments were for
- Consulting fees$1752%
- Food & beverage$7,13195%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $1,243 |
| Novo Nordisk | 74 | $1,092 |
| AstraZeneca | 18 | $775 |
| Abbott | 35 | $654 |
| Lilly USA, LLC | 20 | $415 |
| Pfizer | 27 | $309 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $252 |
| Astellas Pharma US Inc | 8 | $246 |
| Amgen | 13 | $220 |
| Dexcom, Inc. | 12 | $219 |
| Teva Pharmaceuticals USA, Inc. | 11 | $202 |
| Johnson & Johnson(2 entities) | 9 | $197 |
| Exact Sciences | 10 | $192 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $175 |
| Novartis | 11 | $167 |
| Biohaven Pharmaceuticals, Inc. | 12 | $162 |
| Boehringer Ingelheim | 9 | $157 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $155 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| GSK | 7 | $87 |
| Merck | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Idorsia Pharmaceuticals US Inc | 1 | $57 |
| Bayer | 3 | $57 |
| Heartflow, Inc. | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,471 in reported general payments places this provider in the 95th percentile of 361 gerontology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $43,393 |
| EliquisApixaban | 80 | $41,806 |
| OzempicSemaglutide | 39 | $41,316 |
| JanuviaSitagliptin Phosphate | 22 | $34,049 |
| FarxigaDapagliflozin Propanediol | 31 | $23,968 |
| JardianceEmpagliflozin | 22 | $21,558 |
| MounjaroTirzepatide | 19 | $18,392 |
| XareltoRivaroxaban | 13 | $17,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,808 |
| MyrbetriqMirabegron | 16 | $7,593 |
| LinzessLinaclotide | 12 | $6,780 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,390 |
| Atorvastatin Calcium | 322 | $2,921 |
| Gabapentin | 115 | $1,688 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $415 | $61,78557 claims |
| PfizerEliquis | $309 | $41,80680 claims |
| Novo NordiskOzempic | $1,092 | $41,31639 claims |
| MerckJanuvia | $72 | $34,04922 claims |
| AstraZenecaFarxiga | $775 | $23,96831 claims |
| Boehringer IngelheimJardiance | $157 | $21,55822 claims |
| Johnson & JohnsonXarelto | $197 | $17,17313 claims |
| GSKTrelegy Ellipta | $87 | $11,80816 claims |
| Astellas Pharma US IncMyrbetriq | $246 | $7,59316 claims |
| AbbVieLinzess | $1,243 | $6,78012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 gerontology providers in Ohio.
Other gerontology in Cincinnati
- Diana SutherlandCincinnati$32K
- John ShinnCincinnati$26K
- Amy MalmedahlCincinnati$11K
- Lauren GettelfingerCincinnati$8K
- Cheryl HerrleCincinnati$4K
- Jeanette MeyerCincinnati$3K
- Kimberly LeveringCincinnati$2K
- Sunshine BarhorstCincinnati$2K
- Christopher GoddardCincinnati$2K
- Kathryn DinhCincinnati$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.